Gilead Sciences, Inc. Dossier
Qualitative Analysis
Business overview
Gilead Sciences, Inc. is a leading global biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of highly unmet medical need. For over three decades, the company has pioneered breakthroughs in medicine, establishing a commanding market position in virology, particularly in HIV and viral hepatitis. Gilead's core commercial engine is anchored by blockbuster HIV therapies, notably Biktarvy and Descovy. In recent years, Gilead has strategically diversified its portfolio into oncology and cell therapy through organic pipeline development and high-profile acquisitions, transforming itself into a multi-franchise biopharmaceutical platform.
Research as of 5 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Gilead is extending lenacapavir across twice-yearly injectable HIV prevention, once-weekly oral prevention and a once-weekly treatment combination with Merck's islatravir. The commercial program is paired with no-profit supply and voluntary licensing intended to accelerate access in resource-limited countries.
Gilead is broadening Trodelvy into first-line metastatic triple-negative breast cancer, preparing anito-cel for a potential multiple-myeloma launch, and integrating Tubulis' TUB-040, TUB-030 and ADC technology platform.
Gilead is expanding beyond its historical antiviral and oncology focus through Ouro Medicines' gamgertamig T-cell engager and LEO Pharma's oral STAT6 inhibitor and targeted-protein-degrader programs for inflammatory diseases.
Gilead plans to invest $32 billion in U.S. innovation through 2030. Its Foster City expansion includes a 180,000-square-foot technical-development center, a research building and a biologics manufacturing facility intended to accelerate technology transfer and next-generation biologics development.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
The acquisition gives Gilead full control of anito-cel and its D-Domain platform, eliminates future profit-sharing, milestone and royalty obligations, and supports accelerated development and commercialization in multiple myeloma.
The acquisition adds the clinical-stage ADCs TUB-040 and TUB-030 and an integrated next-generation ADC platform, expanding Gilead's solid-tumor pipeline and internal ADC capabilities.
The acquisition adds gamgertamig, a clinical-stage BCMAxCD3 T-cell engager intended to achieve durable immune reset in severe antibody-mediated autoimmune diseases.
Strategic Partnerships
Both Phase 3 ISLEND studies met their Week 48 primary efficacy endpoints, and the companies plan regulatory submissions globally.
The collaboration gives Gilead global rights to develop, manufacture and commercialize the oral STAT6 program while adding a new preclinical mechanism to its inflammation portfolio.
Terms: LEO Pharma is eligible for up to $1.7 billion, including a $250 million upfront payment, plus tiered high-single-digit to mid-teens royalties on oral STAT6 product sales.
The agreement provides enough Gilead-supplied doses to reach up to two million people in eligible resource-limited countries while licensed generic supply is scaled.